
    
      In this single-center, open-label, nonrandomized, no control, prospective clinical trial, no
      less than 18 CD19+ B-cell relapsed or refractory acute B-cell lymphoblastic leukemia (R/R
      B-ALL) patients will be enrolled. Side effects of CD19 CAR T cells therapy will be monitored.
      The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T
      cells therapy in patients with R/R B-ALL.
    
  